Iran-Israel War: Disrupting Supply Chains, Hiking Costs, And Severely Battering Pharmaceutical Industry

Extended delivery timelines, increasing cost, and fluctuating availability are becoming operational realities. Stakeholders must adapt through proactive planning and inventory management.

Introduction Geopolitical tremors are no longer confined to distant maps, they are systemic shocks that hit close to home, impacting the cost and availability of essential goods. The escalating Iran-Israel conflict is a perfect example. What begins as a regional confrontation has swiftly become a global economic disruptor, with immediate and profound consequences for the healthcare industry. 

The pharmaceutical sector, the backbone of global health, is now caught in the crossfire. Central to this crisis is the Strait of Hormuz, a narrow maritime chokepoint through which nearly 20% of the world’s petroleum liquids flow. This passage is vital not just for energy, but for every industry dependent on petrochemical derivatives, including the chemicals essential for making and packaging medicines. 

India, the “pharmacy of the world,” supplies one in five generic medicines globally. Yet, this success story hides a deep vulnerability: a heavy reliance on imported raw materials. As tensions mount, this dependency exposes India’s pharmaceutical ecosystem to severe risk: crippling production delays, soaring costs, and the looming threat of medicine shortages.

Simultaneously, a silent crisis is unfolding in drug packaging. Packaging crucial for safety, stability, and regulation is suddenly becoming scarce and expensive, driven by rising petrochemical costs and disrupted shipping. Together, these forces are creating a perfect storm that is not just raising costs but forcing a fundamental, permanent shift in how the industry operates, from focusing on lean efficiency to prioritizing robust resilience. This analysis dissects how the Iran-Israel conflict is simultaneously squeezing pharmaceutical manufacturing and packaging, exposing structural weaknesses, and compelling a strategic transformation in the global healthcare supply chain.

India’s Pharmaceutical Paradox

India’s pharmaceutical powerhouse status is built on globalized efficiency. But the factors that brought success, cost optimization, and Just-in-Time (JIT) systems are now critical liabilities.

1. The API Lifeline

Active Pharmaceutical Ingredients (APIs) are the core components of every drug. India imports nearly 70% of its APIs, with dependence reaching 80-90% for critical segments like antibiotics. A substantial portion of these materials travels through global shipping routes that are now high-risk geopolitical zones.

• The Immediate Threat: Disruption in these shipping lanes or port operations instantly jeopardizes the availability of raw materials. Even minor delays can cascade into major production bottlenecks, threatening the continuous supply of life-saving drugs.

2. Price Controls vs. The Cost Tsunami

India’s stringent Drug Price Control Order (DPCO) ensures essential medicines are affordable. While vital for patients, this regulation creates a severe challenge during a global crisis. When API costs, freight charges, and energy expenses surge, pharmaceutical companies cannot easily raise their prices to compensate.

• The Financial Squeeze: Manufacturers face aggressive margin compression. Sustaining operations, let alone investing in R&D or expansion, becomes financially untenable.

3. The Collapse of Just-in-Time (JIT)

JIT inventory models designed to maximize efficiency with minimal stock are effective only in stable environments.

• The Inevitable Outcome: Under sustained disruption, JIT systems guarantee immediate stockouts and production halts. The current crisis has brutally exposed the limitations of prioritizing only efficiency in an unpredictable world.

The Strait of Hormuz

The Strait of Hormuz is more than a geographic chokepoint; it’s a global economic lever. Its instability triggers a chain reaction that hits the pharmaceutical sector directly.

1. The Energy-to-Medicine Chain

Pharmaceutical production from solvents to excipients and intermediates is heavily reliant on petrochemical derivatives. When the flow of oil is threatened:

• Crude prices surge.

• Petrochemical feedstock costs skyrocket.

• Manufacturing expenses climb across the board.

Result: A spike in oil prices translates almost immediately into higher pharmaceutical production costs.

2. Logistics Nightmare

Instability in the Strait forces ships to reroute, pay massive insurance premiums, and face crippling congestion.

• Doubled Transit Times: Supply routes can jump from ~25 days to 40-50 days (e.g., rerouting via the Cape of Good Hope).

• Massive Freight Inflation: Shipping costs can increase 3-5 times due to higher fuel and war-risk premiums.

• Predictability Collapse: The industry's ability to plan and forecast production vanishes, compounding the raw material cost pressures.

The Hidden Crisis: Pharmaceutical Packaging

While API shortages grab headlines, a quieter, equally critical crisis is unfolding in drug packaging. Packaging is indispensable for stability, sterility, compliance, and patient safety. Crucially, it is overwhelmingly dependent on petrochemicals.

1. The Petrochemical Value Chain: From Oil to Blister Pack

The packaging crisis begins with the refining of crude oil into feedstocks (like naphtha). These are then processed into primary petrochemicals (Ethylene, Propylene), which are polymerized into the plastics used for virtually all medical packaging:

• Polyethylene (PE) for bottles and caps.

• Polypropylene (PP) for closures and syringes.

• Polyvinyl Chloride (PVC) for essential blister packs.

The Ripple Effect: As the cost of oil and primary petrochemicals surges due to the Hormuz instability, the price of every polymer used in pharmaceutical packaging follows suit.

• Impact: Blister films, laminates, IV bags, and containers all become significantly more expensive and harder to procure, forcing packaging converters operating on thin margins to either absorb unsustainable losses or pass the costs directly to drug manufacturers.

2. The Financial Squeeze: Stress Across the Value Chain

The combined pressure of rising API costs, soaring packaging expenses, and logistical inflation is creating severe financial stress.

• For Pharma Companies: Regulatory price caps limit their ability to pass costs along, leading to severely reduced profitability and a pause in vital R&D investment.

• For Packaging Manufacturers: Unpredictable raw material costs and volatile procurement cycles increase working capital requirements and pose a risk of financial instability.

Critical Insight: A drug cannot be released without compliant packaging. Packaging is now a bottleneck equal to, if not greater than, API availability.

Client Advisory: Strategic and Operational Impacts on the Indian Pharmaceutical Sector

The current global economic and logistical volatility presents significant and immediate challenges that the Indian pharmaceutical industry must navigate, directly impacting supply chain stability and financial viability.

A. Intensified Supply Chain Strain and Extended Timelines:

The persistent global logistics breakdown, characterized by congested ports, container shortages, and extended international transit times, means delivery timelines for essential raw materials (APIs, KSMs) and finished products will inevitably be extended. For Indian pharmaceutical companies, this translates to:

• Increased Inventory Holding Costs: Longer lead times necessitate holding higher levels of safety stock to prevent stock-outs.

• Production Schedule Disruptions: Unpredictable arrival of critical inputs can lead to stoppages or reduced capacity utilization at manufacturing units.

• Worsened Working Capital Cycle: Cash is tied up in slow-moving inventory and goods in transit for longer periods.

Strategic and Operational Realities for the Indian Pharma Sector

The Indian pharmaceutical industry faces a systemic challenge from global economic volatility and logistics failures, pressuring margins and demanding an operational overhaul.

Core Challenges

Extended global transit times for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) necessitate higher inventory buffers, significantly increasing working capital strain. Simultaneously, the Drugs (Prices Control) Order, 2013 (DPCO) restricts the ability to pass on escalating input costs, leading to margin erosion and constraining investments in R&D and modernization. The shift from Just-in-Time to buffer-based procurement structurally increases operating costs through higher capital requirements and storage expenses.

Mandatory Execution Priorities

To ensure financial stability, companies must implement integrated, resilient strategies focused on:

1. Supply Chain Optimization: Diversifying suppliers and moving to proactive inventory management via sophisticated demand forecasting.

2. Financial Resilience: Strengthening working capital by optimizing credit cycles and aggressive cost-efficiency.

3. Digital Integration: Investing in digital supply chain visibility for real-time decision-making.

4. Regulatory Engagement: Proactively engaging with regulatory bodies to address the cost-price mismatch.

Strategic Shift: Trading Efficiency for Resilience

The current crisis is not a temporary setback; it’s an inflection point forcing a fundamental, permanent change in strategy.

The Transformation Agenda:

1. Inventory Overhaul: Abandoning risky JIT models in favor of Buffer-based inventory systems. The trade-off is higher holding costs for vastly greater resilience.

2. Radical Diversification: Proactively sourcing APIs and key intermediates from multiple geographies and politically stable regions to eliminate single-source dependency.

3. Domestic Self-Reliance: Accelerated investment in domestic API and polymer manufacturing to reduce import vulnerability and build true self-reliance.

4. Logistics Mastery: Securing stability through long-term shipping contracts, premium logistics partnerships, and strategic route diversification.

Conclusion

The Iran-Israel conflict has illuminated a critical truth for global health: Efficiency without resilience is unsustainable. The Strait of Hormuz has become a powerful symbol of global vulnerability, demonstrating how a single geopolitical chokepoint can directly influence the global supply and affordability of life-saving medicines. For India, the path ahead is clear but challenging. We must balance our role as a global leader with the need for domestic self-sustainability. Pharmaceutical companies must fundamentally transition from a model focused purely on cost minimization to one centered on risk mitigation and long-term stability. In a world defined by uncertainty, the foundation of trust, continuity, and patient care rests on one principle: Resilience is no longer optional, it is essential.